Moreen Kamateeka, MBChB, MPH
Makerere University-Johns Hopkins University Research Collaboration (MU-JHU CARE LTD)
Dr. Kamateeka holds a Bachelor of Medicine and Surgery (MBChB) degree from Mbarara University of Science and Technology, Mbarara, Uganda and a Masters degree in Public Health (Global Health) from the University of Manchester, United Kingdom. She has extensive experience in clinical research, particularly in the area of Prevention of Mother to Child Transmission of HIV (PMTCT). She has worked on various large multi-site HIV prevention perinatal clinical trials at Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration in Kampala, Uganda including the HIV Prevention Trials Network (HPTN) 046 study-a phase III multi-site HIV perinatal randomized clinical trial to determine the efficacy and safety of an extended regimen of nevirapine in infants born to HIV infected women to prevent vertical HIV transmission during breastfeeding , the HPTN 027 study-A phase 1 study to evaluate the safety and immunogenicity of ALVAC-HIV vCP 1521 in infants born to HIV-1 infected women in Uganda and the Six weeks extended Niverapine study (SWEN) in Uganda. She is currently working as a Junior Investigator on the PROMISE study-Promoting Maternal and Infant Survival Everywhere, a large multi site Unites States of America National Institute of Health (NIH) supported clinical trial as well as its sub-study P1084s-the bone and kidney health sub study at the MU-JHU site. She is also one of the lead Investigators on an National Institute of Health (NIH) supported PMTCT operational research study, Using enhanced peer group strategies to support PMTCT Option B+ in Uganda.
Her research interests include: HIV/AIDs research particularly in the fields of PMTCT and Tuberculosis as well as other common HIV related opportunistic infections.
• Member of the Uganda Society for Health Scientists (USHS)
• Member of African Network for Care of Children affected by HIV/AIDS(ANNECA)
1. Jim A, Glenn Fowler M, Wang J, et al. Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. AIDS (London, England). 2012; 26(3): 325-333. doi: 10.1097/QAD.0b013e32834e892c
2. Kamateeka M, Barlow-Mosha L, Mubiru M, Lutajumwa M, Mudiope P, Musoke PM. Immunologic and virologic responses to nevirapine based antiretroviral therapy (ART) among HIV-Tuberculosis co-infected Ugandan children on rifampicin based anti-tubercular treatment. HIV/AIDS Res Treat Open J. 2015; 2(1): 27-36. doi: 10.17140/HARTOJ-2-104